(Total Views: 445)
Posted On: 04/09/2019 10:38:56 AM
Post# of 15624
Okay, pretend I am management and present the Company position as made up by me:
The proposed R/S is an important option. We may never use it but between when it is approved and the end of the year we may implement the split. We have not made a decision as to the ratio but it is important that we have the range previously indicated. As to why we need the R/S, first, it gives us a much better chance to be up listed and second, the higher price is likely to draw interest from investors (including institutional investors) that ordinarily would not consider "penny stocks".
Your investment value will not change, you will have less shares at a higher share price. What will change hopefully, is the probability of increased investment interest and that typically does drive share price.
We would like to be able to tell you when our clinical trials will be finished and what we expect will be the conclusions but we can not see into the future nor should we make such extrapolations. We do have science on our side and solid experience among our management group. We hear you and understand your concerns but we must focus on the tasks at hand and work towards completing our studies while continuing to form business associations that may result in meaningful collaborations.
Again, we hear you and hope we will have your continued support as we work through this challenging time.
The proposed R/S is an important option. We may never use it but between when it is approved and the end of the year we may implement the split. We have not made a decision as to the ratio but it is important that we have the range previously indicated. As to why we need the R/S, first, it gives us a much better chance to be up listed and second, the higher price is likely to draw interest from investors (including institutional investors) that ordinarily would not consider "penny stocks".
Your investment value will not change, you will have less shares at a higher share price. What will change hopefully, is the probability of increased investment interest and that typically does drive share price.
We would like to be able to tell you when our clinical trials will be finished and what we expect will be the conclusions but we can not see into the future nor should we make such extrapolations. We do have science on our side and solid experience among our management group. We hear you and understand your concerns but we must focus on the tasks at hand and work towards completing our studies while continuing to form business associations that may result in meaningful collaborations.
Again, we hear you and hope we will have your continued support as we work through this challenging time.
(0)
(0)
